Nancy Whiting
Director/Board Member chez CARIBOU BIOSCIENCES, INC.
Fortune : - $ au 31/03/2024
Profil
Nancy C.
Whiting is currently the Chief Executive Officer & Director at Recludix Pharma, Inc., an Independent Director at Caribou Biosciences, Inc., and an Independent Director at Boundless Bio, Inc. Previously, she held positions as the President, Secretary & Director at Cascadian Therapeutics LLC and as the Executive VP-Strategy, Alliances & Communications at Seagen Inc. Dr. Whiting has a graduate degree from the University of Washington and an undergraduate degree from the University of British Columbia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 | |
BOUNDLESS BIO INC.
-.--% | 28/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Nancy Whiting
| Sociétés | Poste | Début |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24/08/2021 |
| BOUNDLESS BIO, INC. | Director/Board Member | 02/10/2023 |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Chief Executive Officer | 01/09/2021 |
Anciens postes connus de Nancy Whiting
| Sociétés | Poste | Fin |
|---|---|---|
| CASCADIAN THERAPEUTICS INC (USA) | President | - |
| SEAGEN INC. | Public Communications Contact | - |
Formation de Nancy Whiting
| University of Washington | Graduate Degree |
| University of British Columbia | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| BOUNDLESS BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Commercial Services |
